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The war against diabetes through the development of new drugs is an ongoing continuous process to counter the 
alarming global increase in the prevalence of diabetes and its complications, particularly n developing countries 
like India. Unfortunately, the spe d with which our knowledge of diabetes and its effects is expanding is not  
matched by the availability of new drugs. Following the identification of the insulin receptor (IR), its intrinsic 
kinase activity and molecular cloning, many studies have looked at IR as an ideal drug target. This review 
summarizes in brief the latest advancements in this field with particular reference to the current situation in  
respect of the development of orally active insulin mimetics in the treatment of type 2 diabetes.
1. Introduction 
Ever since the discovery of insulin in 1921, the develop-
ment of an orally administered insulin or insulin mimetic 
has been the ‘global wish’ for the treatment of diabetes 
mellitus. Unfortunately, insulin has to be taken as an  
injection simply because it is a protein which is broken up 
and digested by the enzymes of the gut if taken orally. 
Therefore, an oral insulin would both obviate the need for 
injections and more importantly, would closely mimic the 
physiological action of insulin by initial entry into the 
portal circulation. Oral therapies for diabetes mellitus 
have emerged out of this interest and are widely used still 
today. But rather than acting by directly mimicking  
insulin signalling, these drugs act by stimulating  
insulin release (sulphonylureas), potentiating insulin action 
(thiazolidinediones), lowering hepatic glucose production 
(biguanides) or by interacting with other intracellular 
events. The present day diabetic treatment pose the fol-
lowing problems: (i) insulin therapy does not accurately 
emulate normal b-cell function, (ii) oral agents only 
partially correct the multiple cellular disturbances that 
characterize type 2 diabetes, (iii) the present range of 
drugs do not completely normalize or reinstate glucose 
homeostasis, (iv) insulin resistance is still relatively  
impervious to treatment and (v) diabetic patients are still 
at risk of chronic morbidity and premature mortality,  
despi e the assiduous use of the available drugs. There-
fore, it has became quite clear that elucidation of the  
molecular mechanisms of insulin signalling in diabetes 
would be necessary both to identify cellular targets and to 
aid in development of a ‘lead’ drug, most probably an 
orally active insulin mimetic. 
 This is what probably provided the motivation for 
Zhang et al (1999) who for the first time materialized the 
goal of an oral insulin almost within reach (up to the  
preclinical stage). The team of researchers (from USA, 
Sweden and Spain) laboured through some 50,000 poten-
tial compounds and finally zeroed in on one promising 
small non-peptidyl molecule that activated more specifi-
cally the human insulin receptor tyrosine kinase (IRTK) 
and acted as an insulin mimetic in several biochemical 
and cellular assays. The research was supported by Merck 
Research Laboratories and the molecule designated as 
L783,281 (compound 1) was identified as a demethyl-
asterriquinone B-1, after isolation by high throughput 
scr ening of a fungal extract (Pseudomassaria sp.) which 
originated in the African jungles. This elegant work has 
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implications for future therapies for diabetes, and the 
drug, if successful in clinical trials, could in future be 
popped as a pill!. Could this make painful daily pricks of 
insulin injections redundant? 
 
2. Activation of insulin receptor kinase – a key step 
in insulin signalling  
In the past, there have been many failed attempts at trying 
to find an oral substitute for insulin. The cellular response
to insulin is mediated by its binding to the insulin receptor 
(IR). The IR is a heterotetrameric structure consisting of 
two a-subunits (135 kDa) on the outside of the plasma 
membrane connected by disulphide bonds to b-subunits 
(95 kDa) which are transmembrane proteins. Insulin bind-
ing to the a-subunits induces conformational changes that 
lead to autophosphorylation of the membrane-spanning b-
subunits. This in turn, leads to the activation of a tyrosine 
kinase activity which is intrinsic to the cytoplasmic  
domains of the b-subunit. Extensive studies have indi-
cated that the ability of the receptor to autophosphorylate 
and phosphorylate intracellular subst ates is essential for 
its mediation of the complex cellular responses of insulin 
(Kasuga et al 1982; Rosen et al 1983; Yu and Czech 
1984; Ellis et al 1987). Insulin receptors trans-
phosphorylate several immediate substrates (on Tyr resi-
dues), including IR substrate (IRS) proteins 1–4, Shc, and 
Gab 1, each of which provide specific docking sites for 
other signalling proteins containing Src homology 2  
domains (White 1998; White and Yenush 1998). These 
events result in a spectrum of biological responses by  
activating downstream signalling molecules including 
phosphatidylinositol 3-kinase (PI 3-kinase). PI 3-kinase 
has recently assumed great significance as the metabolic 
effects of insulin are primarily activated by PI 3-kinase 
dependent steps. Although the discrete pathways that  
couple PI 3-kinase to glucose regulation remain poorly  
defined, Akt (or protein kinase B), a Ser/Thr kinase known 
to be PI 3-kinase-dependent, appears to be involved in insu-
lin-mediated activation of glucose transport (Kohn et al 
1996) and glycogen synthesis (Alessi and Cohen 1998). 
 The mechanism for activation of IRTK has been a su-
ject of intensive investigation. High resolution structural 
information has been obtained through crystallographic 
studies of IR kinase domain (Hubbard et al 1994;  
Hubbard 1997; Till et al 2001). Based on crystal struc-
tures of the unphosphorylated low activity form, as well 
as the phosphorylated active form of the IR, a model of 
cis-inhibition and trans-activation of the receptor was 
proposed. The unliganded receptors exist in the auto-
inhibitory conformation that prevents access of ATP and 
substrate to the active site. Upon autophosphorylation of 
Tyr1158, Tyr1162, and Tyr1163 in the activation loop, the IR 
kinase undergoes a major conformational change resulting 
in unrestricted access of ATP and substrate to the active 
site and full activation of kinase. More recently, the three-
dimensional structure of insulin receptor bound to insulin 
was determined by electron cryomicroscopy (Luo et al 
1999). The three-dimensional reconstruction of the qua-
ternary structure reveals that the both a-subunits are  
involved in insulin binding and that the two b-subunits are 
poised for trans-autophosphorylation. These structural 
tudies have thus thrown new light on the mlecular basis 
of activation of IR. In a nutshell, activation of the tyrosine 
kinase activity of the insulin receptor represents an essen-
tial and foremost step in the transduction of an insulin 
ignal across the plasma membrane of target cells (figure 1). 
 The central role of the insulin receptor in metabolic and 
growth control has been validated in insulin receptor-null 
mouse models (Accili et al 1996; Joshi et al 1996). Muta-
tions in insulin receptor gene that lead to alterations of 
receptor synthesis, degradation, and function have been 
described in patients with several uncommon syndrome  
associated with severe insulin resistance (Taylor 1992). 
The molecular basis for insulin resistance that precedes, 
r is associated with, common forms of type 2 diabetes 
remains poorly understood. However, several studies have 
shown modest decreases in insulin receptor number  
attributed to down-regulation in response to hyperinsu-
linemia in tissues or cells from type 2 diabetic patients 
(Olefsky 1976; Caro et al 1986). Specific decreases in 
insulin-stimulated receptor tyrosine kinase activity and an 
even more substantial defect in receptor-mediated IRS 
phosphorylation or PI 3-kinase and/or Akt activation have 
be n described using cell types from rodents or human 
subjects with type 2 diabetes (Caro et al 1987; Freiden-
berg et al 1987; Haring et al 1987; Bulangu et al 1990; 
Goodyear et al 1995; Kerouz et al 1997; Krook et al 
1998; Kim et al 1999). Thus, in humans with type 2  
diabetes there are clear defects involving the insulin  
receptor and proximal steps in insulin signalling. The 
message from the above studies is that pharmacological 
intervention aimed at augmenting insulin receptor func-
tion may ultimately prove beneficial in patients with  
diabetes. 
 The studies of Zhang et al (1999) demonstrate that 
L783,281 directly modifies the receptor intracellular  
domain, apparently changing its conformation to one  
favouring tyrosine kinase activity. By enhancing the insu-
lin-stimulated IRTK activation, L783,281 was also stated 
to function as an insulin sensitizer. The selectivity of 
L783,281 towards the insulin receptor, instead of the very 
closely related and more mitogenically active IGF-1  
recept r (84% identical in the kinase domain), is truly 
rem rkable, as the catalytic activities of these two prteins 
are extremely similar. After looking at the effects of 
L783,281 on insulin growth factor-1 receptor (IGF1R),  
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epidermal growth factor receptor (EGFR) and platelet-
derived growth factor receptor (PDGFR), the compound 
was claimed to be more specifically selective for insulin 
receptor activation. The in vivo efficacy of L783,281 was 
also tested in db/db and ob/ob mice in which blood glu-
cose was lowered by 50% over 6 h and about 40% over 7 
days of oral therapy with the drug. The rodent models 
used in this study exhibit insulin resistance due to defi-
cient production or signalling by leptin, the fat-derived 
hormone. At present, it is not clearly understood how the 
activity of L783,281 in these rodent models could be  
extrapolated to human type 2 diabetes, in which neither 
leptin deficiency nor resistance are the fundamental  
defects (Flier 1992). Nevertheless, the fact that exogenous 
insulin or insulin secretagogues improve the metabolic 
defect in many type 2 diabetics suggests that L783,281
would elicit a similar corrective action. In addition to its 
effect on IRTK, L783,281 was also shown to activate 
other components of the insulin signalling pathway such 
as stimulation of PI 3-kinase activity and phosphorylation 
of Akt kinase. As expected, L783,281 did stimulate glu-
cose uptake in rat primary adipocytes and mouse soleus 
muscle. 
 Merck Research Laboratories speculated that their work 
represents a lead from which the directed synthesis of  
ne  compounds with improved features can be derived. 
Indeed, the follow-up work proved this is so and provides 
a role model for the systematic high-throughput natural 
product drug discovery. Zhang and his colleagues (Liu  
et al 2000; Qureshi et al 2000) have recently synthesized  
a number of derivatives of L783,281 (compound 1) and 
tested in a cell-based assay that monitors activation of 
Figure 1. Insulin binds to the extracellular a-subunit of the IR, and induces a conformational change in the kinase domain of the 
transmembrane b-subunit resulting in activation of IR tyrosine kinase, an essential step for the downstream insulin signalling events. 
In type 2 diabetes, part of the insulin resista ce is due to inability of insulin to activate the receptor kinase activity (see box). The 
Merck compound L783,281 is claimed to bypass this defect by specifically activating IR tyrosine kinase. Also depicted in the figure 
are other cellular sites wherein vanadium compounds and synthetic phosphoinositol glycans act. 
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IRTK activity in CHO cells expressing human insulin 
receptor (CHO×IR). One of these derivatives (designated 
as compound 2) found increased the IRTK activity in 
these cells with an EC50 of 300 nM, reflecting a greater 
than 10-fold improvement in the potency compared with 
compound 1. In contrast, a closely related analogue, com-
pound 3, was not effective in activating IRTK in the same 
assay at concentrations up to 100 mM. From the basic  
research and pre-clinical point of view, the results with 
the compound 2 appear very promising. In CHO×IR cells, 
it stimulated tyrosyl phosphorylation of the IR b-subunit 
and IRS-1 as well as phosphorylation of Akt in a dose-
dependent manner. Moreover, the effect of insulin and 
compound 2 on activation of Akt can be blocked by pre-
treatment with wortmannin (an inhibitor of PI 3-kinase), 
suggesting the activation of a PI 3-kinase-dependent 
pathway. Compound 2 stimulated tyrosine kinase activity 
of partially purified native IR and recombinant IR tyro-
sine kinase domain. Their administration o mice was  
associated with increased IR tyrosine kinase activity in 
liver. While oral administration of compound 2 to db/db 
mice elicited significant correction of hyperglycemia, in a 
streptozotocin-induced diabetic mouse model, it potenti-
ated the glucose-lowering effect of insulin. In normal  
rats, compound 2 improved oral glucose tolerance with 
significant reduction in insulin release following glucose 
challenge. Quite interestingly, the additional insulin sensi-
tizing actions other than IRTK activation of the Merck 
compound imply that the compound is unlikely to pose a 
great concern for desensitization of the insulin sig alling 
during long term exposure. In fact, Qureshiet al (2000) 
has stressed that the extent of in vivo IR activation by the 
compound 2 was moderate (as against the exaggerated 
action in CHO×IR artificial sytem) only in part to mimic 
that of insulin with the additional benefits of the com-
pound’s action as an insulin sensitizer. Therefore, the  
results of the potent L783,281 endorses thei  potential 
insulin mimetic and sensitizing effects and raises our 
hopes for the development of a novel class of orally active 
antidiabetic agents. 
 
3. Vanadium and protein tyrosine phosphatases 
The demonstration that the trace element vanadium has 
insulin-like properties in isolated cells and tissues and  
in vivo has generated considerable enthusiasm for its  
potential therapeutic value in human diabetes (Meyero-
vitch et al 1987; Brichard et al 1992; Woo et al 1999; 
Sakurai et al 2000). A major advance in the use of vana-
dium as an insulin-mimetic has been the development of 
organic vanadium complexes (peroxovanadiums, pVs). In 
several studies, administration of pV species resulted in 
activation of IRTK, autophosphorylation at tyrosine resi-
dues and inhibition of phosphotryrosine phosphatases 
(PTPases) (Posner t al 1994; Bevan et al 1995; Grillo  
e  al 2000). Band et al (1997) have established the exis-
tence of an IRTK-associated PTPase whose inhibition by 
pVs correlates closely with IRK tyrosine phosphorylation, 
activation, and downstream signalling. The insulin-mimetic 
properties of the pV compounds raises the possibility for 
their use as insulin replacement in the management of 
d abetes mellitus. Supporting this view, initial clinical 
trials have reported a beneficial effect in patients with 
type 2 diabetes (Cohen et al 1995). Another vanadium 
(IV) compound, KP-102, is also currently under clinical 
trails i  humans (Crans 2000). A few animal studies indi-
cate that oral ammonium dipicolinatooxovnadium (V) is 
a clinically useful hypoglycemic agent in cats with natu-
rally occurring diabetes mellitus. This compound is  
p rticularly interesting since it represents for the first time 
that a well-characterized organic vanadium compound 
with the vanadium in oxidation state five can act as an 
orally effective hypoglycemic agent in animals. A recent 
report has also claimed that transdermal delivery of pV 
compounds should be more beneficial in terms of their 
enhanced insulin mimetic and blood gluc se owering 
properties in rats (Brand and Hamel 1999). Despite these 
advances, there is also concern regarding the usage of 
vanadium in human diabetes, as they lack specificityand 
augment tyrosyl phosphorylation of a wide variety of  
cellular proteins and function in vitro as an inhibitor of 
protein tyrosine phosphatases (Denu et al 1996). Vana-
dium compounds could pose toxicity problems as they 
also target ‘P’ type ATPases, adenylate cyclases and Ca2+ 
channels. The avoidance of chronic toxicity and po ential
carcinogenic effects could be critical issues in the further 
development of vanadium-based insulin mimetics. Further-
more, some of the mechanistic studies indicate that vana-
dium acts not globally, but selectively and by enhancing 
rather than by mimicking the effects of insulin in vivo 
(Cam et al 2000). 
 Vanadium studies point out that protein tyrosine phos-
phatases could also be a suitable target for defining a 
novel class of insulin mimetics. PTPases play a critical 
role in regulating insulin action in part through dephos-
phorylation of the active (autophosphorylated) form of the 
insulin receptor (IRK) and attenuation of its tyrosine 
k nase ctivity. Following insulin binding, the activated 
IRK is rapidly internalized into the endosomal apparatus, 
a major site at which the IRK is dephosphorylated in vivo. 
Tyrosine phospatases such as PTP1B and PTPa are 
known to dephosphorylate the insulin receptor and may 
co tribute to insulin resistance in diabetes mellitus. In 
support of this view, overexpression of PTP1B in rat adi-
pose cells significantly impairs insulin-stimulated trans-
location of GLUT4 (Chen et al 1997). Additionally, a 
phosphotyrosyl mimetic peptide reverses impairment of 
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insulin-stimulated translocation of GLUT4 caused by 
overexpression of PTP1B in rat adipose cells (Chen et al 
1999). These studies suggest that PTP1B is implicated in 
the attenuation of the insulin signalling. Moreover, mice 
deficient in the heterotrimeric GTP-binding protein sub-
unit Gia2 exhibit a phenotype of insulin resistance charac-
teristic of type 2 diabetes that correlates with the 
increased expression of PTP1B (Moxham and Malbon 
1996). However, the most convincing results for PTP1B 
and insulin receptor interaction came from the recent 
studies of Elchebly et al (1999) in which mice lacking 
PTP1B gene showed increased insulin sensitivity and  
obesity resistance. Additionally, a specific molecular  
basis for the dephosphorylation of the activation segment 
of the insulin receptor by PTP1B has been recently  
reported through crystallographic, kinetic and PTP1B 
peptide binding studies (Salmeen et al 2000). These  
results make PTP1B a potential therapeutic target for the 
treatment of type 2 diabetes and obesity. Infact, Novo 
Nordisk has already on its way to optimizing a lead com-
pound from the recently identified 2-(oxalylamino)-
benzoic acid (OBA) which is a relatively weak, nonphos-
phorus, nonpeptidal inhibitor of several PTPases (Ander-
sen et al 2000). This optimization process of structure-
based design, guided by PTP mutants and X-ray protein 
crystallogrpahy has been expected to yield a highly selec-
tive, low molecular weight PTP1B inhibitor with unique 
enzyme kinetic features (Iversen t al 2000). It is also 
expected that new inhibitors of PTP1B may arise from the 
optimization of a series of azolidinediones (Malamas et al 
2000) and from bioactive compounds extracted from  
cinnamon (Imparl-Radosevich et al 1998). Since PTP1B 
inhibitors may have the same therapeutic potential as IR 
kinase activators, there is also much scope in the deve-
lopment of new specific inhibitors of PTP1B-IRK inter-
action(s). 
4. Synthetic phosphoinositolglycans (PIG peptides) 
mimic insulin by activating PI 3-kinase pathway 
PI 3-kinase plays an important role in various insulin-
stimulated biological responses including glucose trans-
port, glycogen synthesis, and protein synthesis (Isakoff  
et al 1995; Quon et al 1995). Subcellular fractionation 
analyses indicates that insulin, unlike other growth fac-
tors, stimulates PI 3-kinase activity not only in the plasma 
membrane fraction but also in the low density microsomal 
compartment and possibly even in GLUT4 containing 
subfractions of the low density microsomes of adipocytes 
(Clark et al 1998). It appears that insulin-mediated sub-
compartmentalization of PI 3-kinase may be unique and 
might be key to the specificity of the effect of insulin on 
glucose transport. Earlier studies indicate that activation 
of PI 3-kinase was necessary but not sufficient for stimu-
lation of glucose transporter translocation in insulin-
sensitive cells (Jiang et al 1998) similar to the actions  
of other signals such as platelet-derived growth factor 
(PDGF) and interleukin 4, which stimulate PI 3-kinase 
without any detectable GLUT translocation (Gould et al 
1994; Isakoff et al 1995). However, it is now clear from 
the studies of Egawa et al (1999) that expression of the 
membrane-targeted p110 subunit of PI 3-kinase in 3T3-L1 
adipocytes was sufficient to induce PI 3-kinase-dependent 
downstream signalling events, including glucose trans-
port. Recently, synthetic phosphoinositolglycan (PIG) 
peptides have also been d monstrated to exert insulin-
mimetic activity on glucose and lipid metabolism in insulin-
nsitive cells and tissues in vitro and in vivo (Frick  
et al 1998). PIG peptides are designed according to the 
consensus structure of yeast glycosyl-ph phoinositol 
(GPI) anchors of GPI proteins and in rat adipocytes their 
activity depends on the presence of a 115 kD polypep-
tide residing in plasma membrane caveolae where they 
interact with GPI proteins as the natural ligands. In mim-
icking the metabolic insulin sigalling at the cellular 
level, PIG compounds are more selective for the phospho-
inositol 3-kinase (PI 3-K) than mitogen-activated protein 
kinase (MAPK). These compounds although not activa-
ting IR kinase, recruit insulin signalling by invoking tyro-
sine phosphorylation of IRS-1, as evident from their 
i sulin-mimetic activity in receptor-depleted adipocytes 
(Kessler et al 1998). Therefore, insulin and PIG peptide 
signalling seems to be divergent upstream of IRS-1 but 
converge at the level of PI 3-Kinase resulting in activation 
of further downstream signals and glucose uptake. In  
response to insulin, a decreased IRS-associated PI 3-
kinase activity and a selective resistance to PI 3-kinase 
pathway were demonstrated in the vascular tissues of 
obese Zucker rats (Jiang et al 1999). Therefore, it is sug-
gested that the early signall ng step(s) used by PIG may 
represent a target for the treatment of insulin-res stant 
states and/or type 2 diabetes. At present, synthesis of  
potent and economical insulin-mimic PIG molecules are 
being carried out along with a strategy for conversion of 
the peptide and carbohydrate portions into heterocyclic 
structures which exhibit advantages with regard to oral 
delivery and bioavailability. 
5. Future research 
The new millennium holds promise of an explosion of 
novel anti-diabetic agents. Even in the case of wonder 
drug in ulin, there have been several attempts to create an 
insulin which will not self aggregate and will exist in 
monomer form, get absorbed quickly and dissipate raidly
to mimic a physiological release of insulin. Insulin 
Glargine (Lantus) is the most recent addition to the  
growing family of insulin analogues and formulations  
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(‘designer insulins’) which release insulin in vivo in a 
relatively constant and thus peakless profile over 24 h 
with an additional advantage of restricting hepatic glucose 
production over prolonged periods (Heinmann et l 
2000). It is certain that the biotechnological advancements 
are going to yield more ‘design r’ insulins in the near 
future. Specific strategies to overcome the barriers to oral 
insulin administration are also underway with the use of 
permeation enhancers, protease inhibitors, enteric coat-
ings, polymer microsphere formulations and other drug 
delivery techniques (Carino and Mathiowitz 1999;  
Marschutz and Bernkop-Schnurch 2000; Marschutz et al 
2000). In this context the effort for identifying, optimizing 
and developing specific insulin mimics has to go a long 
way to compete with the present day developments in the 
orally available insulin. However, correction of the exact 
biochemical defect by the molecular targeting of an insu-
lin mimic will in theory, could be an advantageous ther-
apy in certain subpopulations of type 2 diabetes and/or 
insulin resistant patients. Therefore, new chemical entities 
interfering with protein kinase and/or phosphatase inter-
action with insulin receptor can also be valuable pharm-
cological agents in the treatment of type 2 diabetes. It 
would be ideal if the newer drugs also possess insulin-
independent blood glucose lowering activities and exhibit 
extrapancreatic actions that would improve the insulin 
sensitivity of the peripheral tissues and the reduction in 
hepatic insulin uptake. In fact, one of the reasons for the 
renewed interest in new generation sulphonylureas (e.g. 
glimepiride) in clinical diabetes rests on their beneficial 
extrapancreatic actions (Muller 2000). The studies on 
insulin mimics, including the pre-clinical investigations of 
Merck compounds thus raise much hope for the develop-
ment of newer anti-diabetic drugs derived from the nature. 
Global traditional medicine also has great promise of a 
number of plants and plant products with anti-d abetic 
activity (Bailey and Day 1989; Balasubramanyam and 
Mohan 1999). A simple mushroom (Agaricus campestris) 
has been recently documented to have antihypergly-
caemic, insulin-releasing and insulin-like activity (Gray 
and Flatt 1998). Ipomoea aquatica that is commonly con-
sumed as a green leafy vegetable in several parts of South 
Asia is reported to possess an insulin-like activity (Mala-
lavidhane t al 2000). It is high time for us to fully exploit 
our medicinal biodiversity to look for new chemical enti-
ties using high throughput biological screening assays. It 
is possible that many insulin mimetic properties may lie 
hidden in plants of Indian jungles and tribal areas!  
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